| Table III.2: States Reporting Whether Drug Compounding for Office Use is Authorized or Allowed in Their State | |||
|---|---|---|---|
| Drug compounding for office use authorized or allowed | |||
| State | Yes | No | No response |
| Alabama | ✓ | ||
| Arizona | ✓ | ||
| Arkansas | ✓ | ||
| California | ✓ | ||
| Colorado | ✓ | ||
| Connecticut | ✓ | ||
| Delaware | ✓ | ||
| District of Columbia | ✓ | ||
| Florida | ✓ | ||
| Georgia | ✓ | ||
| Guam | ✓ | ||
| Hawaii | ✓ | ||
| Idaho | ✓ | ||
| Illinois | ✓ | ||
| Iowa | ✓ | ||
| Kansas | ✓ | ||
| Kentucky | ✓ | ||
| Louisiana | ✓ | ||
| Maine | ✓ | ||
| Maryland | ✓ | ||
| Massachusetts | ✓ | ||
| Michigan | ✓ | ||
| Minnesota | ✓ | ||
| Mississippi | ✓ | ||
| Missouri | ✓ | ||
| Montana | ✓ | ||
| Nebraska | ✓ | ||
| Nevada | ✓ | ||
| New Hampshire | ✓ | ||
| New Jersey | ✓ | ||
| New Mexico | ✓ | ||
| New York | ✓ | ||
| North Carolina | ✓ | ||
| North Dakota | ✓ | ||
| Ohio | ✓ | ||
| Oklahoma | ✓ | ||
| Oregon | ✓ | ||
| Pennsylvania | ✓ | ||
| Rhode Island | ✓ | ||
| South Carolina | ✓ | ||
| South Dakota | ✓ | ||
| Tennessee | ✓ | ||
| Texas | ✓ | ||
| Utah | ✓ | ||
| Vermont | ✓ | ||
| Virginia | ✓ | ||
| Washington | ✓ | ||
| West Virginia | ✓ | ||
| Wisconsin | ✓ | ||
| Wyoming | ✓ | ||
| Source: GAO survey of state pharmacy regulatory bodies, survey question 13. | GAO-17-363SP |
| Notes: GAO surveyed the state pharmacy regulatory bodies in the 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands, and all but 4 completed the survey. |
| Drug compounding for office use is the compounding of a drug product, without an individual patient prescription, to be kept as stock in a doctor’s office, hospital, or other health care facility. |